Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 9/20 | 0.44 |
| ▸ | TLR2 | O60603 | 3/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29521884 | 0.94 | TLR2 (0.41) | ALBTLR2TLR1MDM2 | |
| SCHEMBL22021730 | 0.92 | TLR2 (0.41) | ALBTLR2TLR1KMT2AMDM2 | |
| SCHEMBL31298693 | 0.92 | ALB (0.48) | ALBTLR2TLR1CA9 | |
| SCHEMBL20530026 | 0.91 | ALB (0.53) | ALBTLR2KMT2ACA9MDM2 | |
| SCHEMBL20530037 | 0.90 | ALB (0.47) | ALBTLR2CA9MDM2 | |
| SCHEMBL31298675 | 0.90 | ALB (0.47) | ALBTLR2CA9MDM2 | |
| SCHEMBL31298682 | 0.89 | PTPN1 (0.41) | TLR2TLR1KMT2A | |
| SCHEMBL20450572 | 0.88 | KMT2A (0.49) | TLR2TLR1KMT2AMDM2KLK7 | |
| SCHEMBL20450575 | 0.88 | KMT2A (0.57) | TLR2TLR1KMT2AMEN1ALDH1A1 | |
| SCHEMBL20450573 | 0.88 | KMT2A (0.57) | TLR2TLR1KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377175-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | CORNELL UNIVERSITY (US) | 2025-08-05 | — | — | US | disclosed |
| US-12268759-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | CORNELL UNIVERSITY (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240050599-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2024-02-15 | — | — | US | disclosed |
| US-20230285603-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230114130-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | COMELL UNIVERSITY (US) | 2023-04-13 | — | — | US | disclosed |
| US-11285227-B2 | Trifunctional constructs with tunablepharmacokinetics useful in imaging and anti-tumor therapies | CORNELL UNIVERSITY (US) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11285227-B2 | Trifunctional constructs with tunablepharmacokinetics useful in imaging and anti-tumor therapies | MC2R, OGFR, GLS | ALB 3175/4885TLR2 4118/4885TLR1 3839/4885 |
| US-20230114130-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, KRAS | ALB 2124/4885TLR2 4003/4885TLR1 3865/4885 |
| US-20230285603-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | ALB 2495/4885TLR2 4148/4885TLR1 4326/4885 |
| US-20240050599-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | ALB 2495/4885TLR2 4148/4885TLR1 4326/4885 |
| US-12377175-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | VHL, GLS, GPER1 | ALB 2495/4885TLR2 4148/4885TLR1 4326/4885 |
| US-12268759-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | VHL, GLS, GPER1 | ALB 2495/4885TLR2 4148/4885TLR1 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.